By Ahmed Aboulenein WASHINGTON (Reuters) -Current laws and regulations are not enough to protect Americans from the risks of ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ... a ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.